FIGURE 1.

Sample collection and tumour mutation burden in cervical cancer. (A) The cohort study included 135 patients with cervical cancer (FIGO stages IB1–IIB) who received neoadjuvant cisplatin‐based chemotherapy. Patients were classified into drug‐resistant patients’ group (n = 48) and drug‐sensitive patients’ group (n = 87) according to the disease progression after treatment. WES was performed for each prechemotherapy tumour tissue and peripheral blood pair. (B) Representative radiological and pathological images of drug‐resistant and drug‐sensitive patients. The white arrows indicated the lesion sites